Association of MR-proadrenomedullin with cardiovascular risk factors and subclinical cardiovascular disease

• Published in: Atherosclerosis 2013-06, Vol.228 (2), p.451-459
• Main Authors: Neumann, Johannes Tobias, Tzikas, Stergios, Funke-Kaiser, Anne, Wilde, Sandra, Appelbaum, Sebastian, Keller, Till, Ojeda-Echevarria, Francisco, Zeller, Tanja, Zwiener, Isabella, Sinning, Christoph R, Jagodzinski, Annika, Schnabel, Renate B, Lackner, Karl J, Münzel, Thomas, Blankenberg, Stefan, Wild, Philipp S, Sydow, Karsten
• Format: Article
• Language: English
• Subjects: Adrenomedullin; Adrenomedullin - blood; Adult; Age Factors; Aged; Asymptomatic Diseases; atherosclerosis; Biomarker; biomarkers; Biomarkers - blood; Cardiovascular; Cardiovascular disease; Cardiovascular Diseases - blood; Cardiovascular Diseases - diagnosis; Cardiovascular Diseases - epidemiology; Cardiovascular Diseases - physiopathology; Cardiovascular risk factors; cardiovascular system; Cross-Sectional Studies; diabetes; dyspnea; Echocardiography; Female; fluorescent antibody technique; Fluoroimmunoassay; Germany - epidemiology; heart failure; Humans; hyperlipidemia; hypertension; Linear Models; Male; men; Middle Aged; myocardial infarction; normal values; patients; Peptide Fragments - blood; Phenotype; Predictive Value of Tests; Prevalence; Prognosis; Prospective Studies; Protein Precursors - blood; Reference values; Risk Assessment; Risk Factors; Sex Factors; stroke; Up-Regulation; women
• ISSN: 0021-9150; 1879-1484
• DOI: 10.1016/j.atherosclerosis.2013.03.006

Abstract Aims and background Midregional proadrenomedullin (MR-proADM) is a protein, which exerts various effects on the cardiovascular system. Recent studies underscored its prognostic implications in patients with acute dyspnea and cardiovascular diseases. Therefore, we aimed to determine the distribution of MR-proADM in the general population and to reveal potential associations of MR-proADM with cardiovascular risk factors and measures of subclinical cardiovascular disease. Methods and results MR-proADM plasma concentrations were determined in individuals of the population-based cohort of the Gutenberg Health Study ( N  = 5000) using a commercially available fluoroimmunoassay. Individuals were enrolled between April 2007 and October 2008. Subclinical cardiovascular disease was assessed using echocardiographic and functional measures of myocardial and vascular function. The mean age of the study population was 55.5 ± 10.9 years. In the overall population we determined a median MR-proADM plasma concentration of 0.44 nmol/L in men and women. MR-proADM concentrations were elevated in individuals with hypertension, diabetes, dyslipidemia, known cardiovascular disease, heart failure, peripheral artery disease, atrial fibrillation, and history of myocardial infarction and stroke. In men, we observed a positive association of MR-proADM with reduced ejection fraction, intraventricular septal diameter, wall thickness, and echocardiographic measures of diastolic dysfunction. Conclusions In this study, we present age-dependent reference values for MR-proADM in a representative population sample. Elevated MR-proADM plasma concentrations were strongly associated with classical cardiovascular risk factors and manifest cardiovascular diseases. Furthermore, we revealed a gender-specific association with echocardiographic measures of hypertension. MR-proADM seems to be a promising prognostic biomarker for subclinical and manifest cardiovascular disease.